A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes

Trial Profile

A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Cannabidiol (Primary) ; Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Tetrahydrocannabivarin 9 (Primary)
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2016 Results assessing effects of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters published in the Diabetes Care (2016).
    • 05 May 2016 Results from this trial are expected in Q2/3 2016, according to a GW Pharmaceuticals media release.
    • 28 Nov 2012 Primary endpoint 'HDL-cholesterol-level' has not been met based on information reported in a GW Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top